Addressing Origins of the Opioid Epidemic by Improving Prescribing for

Status Completed

Clinical Trial Summary

Risk of long-term opioid dependence increases with initial opioid dose/duration, but despite recent Centers for Disease Control and Prevention (CDC)-endorsed minimum doses for initial opioid prescription, primary care providers are likely to overprescribe. In this quality improvement project, primary care departments at Weill Cornell and the Institute for Family Health (federally qualified health center in New York City) will implement an unobtrusive "nudge" in their electronic prescribing software to promote the CDC-endorsed low doses for all opioids. In the evaluation, we will employ a quasi-experimental design with rigorous interrupted time series analysis methods to assess the effect of the "nudge" on prescribing rates. The analysis will be performed at the provider level, with deidentified physician data and a limited data set (fully deidentified except for date of prescription) of patient-level data.

Clinical Trial Description

The two participating institutions, WCMC (Weill Cornell Medical College) and IFH (Institute for Family Health), intend to redesign the e-prescribing interface to create a minor "nudge" to encourage prescribers to prescribe the minimum dose set by the 2016 CDC guideline for opioid-naive patients in 2018. The change to the e-prescribing system is that after a prescriber chooses the drug they wish to prescribe, the minimum recommended dosage from the CDC guidelines will be displayed. The prescriber can choose to change the dosage by overwriting in the field box. The changes to the prescriber system will be implemented at two Weill Cornell clinical organizations: Weill Cornell Internal Medicine Associates (WCIMA) and Weill Cornell Medical Associates (CMA), and at all locations at our collaborating institution IFH (Institute for Family Health). Weill Cornell and IFH will provide data for the analysis, which will be conducted by the co-investigators on this protocol. The project will assess data pre- and post- implementation to study prescribing patterns. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03377855
Study type	Interventional
Source	Weill Medical College of Cornell University
Contact
Status	Completed
Phase	N/A
Start date	February 1, 2018
Completion date	December 31, 2019

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04095624` - Does Preoperative Pain Medication Management Influence Surgical Outcomes in Spinal Fusion	N/A
Completed	`NCT04484610` - Appropriate Opioid Quantities for Acute Pain - Pharmacist Study	Phase 4
Recruiting	`NCT04598074` - Opioid Package Prototype (OPP)	N/A
Recruiting	`NCT06033599` - Motivational Interviewing and Mindfulness-Oriented Recovery Enhancement	Phase 3
Recruiting	`NCT06032559` - Implementation and Effectiveness of Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment	Phase 3
Completed	`NCT05845177` - Persistent Pain After Hip Replacement
Completed	`NCT03570320` - Does Altering Narcotic Prescription Methods Affect Opioid Distribution Following Select Upper Extremity Surgeries?	N/A
Completed	`NCT03268551` - MEMO-Medical Marijuana and Opioids Study
Completed	`NCT04526236` - Influence of Aging on Perioperative Methadone Dosing	Phase 4
Completed	`NCT05593341` - Opioid Education in Total Knee Arthroplasty	N/A
Recruiting	`NCT05877157` - Pain AND Opioids After Surgery
Recruiting	`NCT06055205` - A Pain and Coordination Plan for Reduced Opioid Use After Accidental Injuries	N/A
Recruiting	`NCT03675386` - Reducing Opioid Use for Chronic Pain Patients Following Surgery	N/A
Suspended	`NCT05001789` - Cognitive Functioning in Opioid Use Disorder	N/A
Completed	`NCT04296396` - Opioid Prescription After Cesarean Trial	Phase 3
Not yet recruiting	`NCT04868552` - Naloxone Education in Total Joint Patients	N/A
Completed	`NCT03540030` - Opioid-Free Shoulder Arthroplasty	Phase 4
Terminated	`NCT06217380` - Feasibility and Acceptability of Oxygen Saturation Monitoring Using Masimo SafetyNet Alert (MSNA) in a Supportive Housing Program	N/A
Recruiting	`NCT05976646` - Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion	Phase 1/Phase 2
Completed	`NCT03472521` - Prevention of Persistent Opioid Use in Mothers	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Addressing Origins of the Opioid Epidemic by Improving Prescribing for Opioid-Naive Patients

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms